Anti-Helicobacter pylori activity of ethoxzolamide

References

• Hooi JKY, Lai WY, Ng WK, et al. Global prevalence of Helicobacter pylori infection: systematic review and meta-analysis. Gastroenterology 2017;153:420–9.
   PubMed Web of Science ®Google Scholar
• Take S, Mizuno M, Ishiki K, et al. Seventeen-year effects of eradicating Helicobacter pylori on the prevention of gastric cancer in patients with peptic ulcer; a prospective cohort study. J Gastroenterol 2015;50:638–44.
   PubMed Web of Science ®Google Scholar
• Graham DY. Helicobacter pylori update: gastric cancer, reliable therapy, and possible benefits. Gastroenterology 2015;148:719–31.
   PubMed Web of Science ®Google Scholar
• Uemura N, Okamoto S, Yamamoto S, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001;345:784–9.
   PubMed Web of Science ®Google Scholar
• Shiota S, Reddy R, Alsarraj A, et al. Antibiotic resistance of Helicobacter pylori among male United States veterans. Clin Gastroenterol Hepatol 2015;13:1616–24.
   PubMed Web of Science ®Google Scholar
• Savoldi A, Carrara E, Graham DY, et al. Prevalence of antibiotic resistance in Helicobacter pylori: a systematic review and meta-analysis in World Health Organization regions. Gastroenterology 2018;155:1372–82.
   PubMed Web of Science ®Google Scholar
• Marcus EA, Scott DR. Gastric colonization by H. pylori. In: Kim N, ed. Helicobacter pylori. Singapore: Springer; 2016:23–34.
   Google Scholar
• Eaton KA, Krakowka S. Effect of gastric pH on urease-dependent colonization of gnotobiotic piglets by Helicobacter pylori. Infect Immun 1994;62:3604–7.
   PubMed Web of Science ®Google Scholar
• Eaton KA, Brooks CL, Morgan DR, Krakowka S. Essential role of urease in pathogenesis of gastritis induced by Helicobacter pylori in gnotobiotic piglets. Infect Immun 1991;59:2470–5.
   PubMed Web of Science ®Google Scholar
• Sachs G, Weeks DL, Wen Y, et al. Acid acclimation by Helicobacter pylori. Physiology 2005;20:429–38.
   PubMed Web of Science ®Google Scholar
• Ronci M, Del Prete S, Puca V, et al. Identification and characterization of the α-CA in the outer membrane vesicles produced by Helicobacter pylori. J Enzyme Inhib Med Chem 2019;34:189–95.
   PubMed Web of Science ®Google Scholar
• Nishimori I, Minakuchi T, Morimoto K, et al. Carbonic anhydrase inhibitors: DNA cloning and inhibition studies of the alpha-carbonic anhydrase from Helicobacter pylori, a new target for developing sulfonamide and sulfamate gastric drugs. J Med Chem 2006;49:2117–26.
   PubMed Web of Science ®Google Scholar
• Nishimori I, Onishi S, Takeuchi H, Supuran CT. The alpha and beta classes carbonic anhydrases from Helicobacter pylori as novel drug targets. Curr Pharm Des 2008;14:622–30.
   PubMed Web of Science ®Google Scholar
• Modak JK, Modakh JK, Liu YC, et al. Structural basis for the inhibition of Helicobacter pylori α-carbonic anhydrase by sulfonamides. PLoS One 2015;10:e0127149.
   PubMed Web of Science ®Google Scholar
• Modak JK, Liu YC, Supuran CT, Roujeinikova A. Structure-activity relationship for sulfonamide inhibition of Helicobacter pylori α-carbonic anhydrase. J Med Chem 2016;59:11098–109.
   PubMed Web of Science ®Google Scholar
• Puscas I, Buzas G. Treatment of duodenal ulcers with ethoxzolamide, an inhibitor of gastric mucosa carbonic anhydrase. Int J Clin Pharmacol Ther Toxicol 1986;24:97–9.
   PubMed Web of Science ®Google Scholar
• Vălean S, Vlaicu R, Ionescu I. Treatment of gastric ulcer with carbonic anhydrase inhibitors. Ann N Y Acad Sci 1984;429:597–600.
   PubMed Web of Science ®Google Scholar
• Puscas I. Treatment of gastroduodenal ulcers with carbonic anhydrase inhibitors. Ann N Y Acad Sci 1984;429:587–91.
   PubMed Web of Science ®Google Scholar
• Graham D, Lew GM, Klein D, et al. Effect of treatment of Helicobacter pylori infection on the long-term recurrence of gastric or duodenal ulcer. A randomized, controlled study. Ann Intern Med 1992;116:705–8.
   PubMed Web of Science ®Google Scholar
• Haas R, Meyer TF, van Putten JP. Aflagellated mutants of Helicobacter pylori generated by genetic transformation of naturally competent strains using transposon shuttle mutagenesis. Mol Microbiol 1993;8:753–60.
   PubMed Web of Science ®Google Scholar
• Akopyants NS, Eaton KA, Berg DE. Adaptive mutation and cocolonization during Helicobacter pylori infection of gnotobiotic piglets. Infect Immun 1995;63:116–21.
   PubMed Web of Science ®Google Scholar
• Lee A, O'Rourke J, De Ungria MC, et al. A standardized mouse model of Helicobacter pylori infection: introducing the Sydney strain. Gastroenterology 1997;112:1386–97.
   PubMed Web of Science ®Google Scholar
• Alm RA, Ling LS, Moir DT, et al. Genomic-sequence comparison of two unrelated isolates of the human gastric pathogen Helicobacter pylori. Nature 1999;397:176–80.
   PubMed Web of Science ®Google Scholar
• Clinical and Laboratory Standards Institute. 2015. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard, 10th ed, supplement M07-A10. Wayne, PA: Clinical and Laboratory Standards Institute.
   Google Scholar
• Makobongo MO, Kovachi T, Gancz H, et al. In vitro antibacterial activity of acyl-lysyl oligomers against Helicobacter pylori. Antimicrob Agents Chemother 2009;53:4231–9.
   PubMed Web of Science ®Google Scholar
• Clinical and Laboratory Standards Institute. 2016. Methods for antimicrobial dilution and disk susceptibility testing of infrequently isolated or fastidious bacteria. 3rd ed. CLSI guideline M45. Wayne, PA: Clinical and Laboratory Standards Institute.
   Google Scholar
• Haas CE, Nix DE, Schentag JJ. In vitro selection of resistant Helicobacter pylori. Antimicrob Agents Chemother 1990;34:1637–41.
   PubMed Web of Science ®Google Scholar
• Wang G, Wilson TJ, Jiang Q, Taylor DE. Spontaneous mutations that confer antibiotic resistance in Helicobacter pylori. Antimicrob Agents Chemother 2001;45:727–33.
   PubMed Web of Science ®Google Scholar
• Kulick S, Moccia C, Kraft C, Suerbaum S. The Helicobacter pylori mutY homologue HP0142 is an antimutator gene that prevents specific C to A transversions. Arch Microbiol 2008;189:263–70.
   PubMed Web of Science ®Google Scholar
• Quigley EM, Turnberg LA. pH of the microclimate lining human gastric and duodenal mucosa in vivo. Studies in control subjects and in duodenal ulcer patients. Gastroenterology 1987;92:1876–84.
   PubMed Web of Science ®Google Scholar
• Petschow BW, Batema RP, Ford LL. Susceptibility of Helicobacter pylori to bactericidal properties of medium-chain monoglycerides and free fatty acids. Antimicrob Agents Chemother 1996;40:302–6.
   PubMed Web of Science ®Google Scholar
• Nishizawa T, Suzuki H. Mechanisms of Helicobacter pylori antibiotic resistance and molecular testing. Front Mol Biosci 2014;1:19.
   PubMed Web of Science ®Google Scholar
• Kuo CJ, Guo RT, Lu IL, et al. Structure-based inhibitors exhibit differential activities against Helicobacter pylori and Escherichia coli undecaprenyl pyrophosphate synthases. J Biomed Biotechnol 2008;2008:841312.
   PubMedGoogle Scholar
• Maren TH, Brechue WF, Bar-Ilan A. Relations among IOP reduction, ocular disposition and pharmacology of the carbonic anhydrase inhibitor ethoxzolamide. Exp Eye Res 1992;55:73–9.
   PubMed Web of Science ®Google Scholar
• Swenson ER. Safety of carbonic anhydrase inhibitors. Expert Opin Drug Saf 2014;13:459–72.
   PubMed Web of Science ®Google Scholar